单域抗体核素显像可无创定量肿瘤浸润白细胞LAG-3表达并预测免疫检查点阻断疗效
本研究利用放射性标记的单域抗体,在小鼠同种移植肿瘤模型中通过SPECT/CT进行全身LAG-3表达显像。结果显示注射后1小时即可检测到肿瘤浸润淋巴细胞上的LAG-3表达,并能可视化PD-1阻断后TILs上LAG-3的代偿性上调。PD-1与LAG-3联合阻断观察到肿瘤生长延迟的协同效应,提示该技术可用于无创监测LAG-3动态变化并预测治疗结局。
要点
- 放射性标记单域抗体可在注射后1小时检测肿瘤浸润淋巴细胞的LAG-3表达。
- 该显像可可视化PD-1阻断后MC38肿瘤中TILs上LAG-3的代偿性上调。
- PD-1与LAG-3联合阻断在MC38荷瘤小鼠中观察到肿瘤生长延迟的协同效应。
核心结论
- 研究结果巩固了LAG-3作为下一代免疫检查点的地位,并支持单域抗体用于无创监测TILs上LAG-3表达的动态演变,以预测治疗结局。
研究设计与样本
- 临床前研究,在多种同种移植小鼠癌症模型中使用放射性标记单域抗体进行SPECT/CT显像,注射后1小时扫描。
- 离体器官和肿瘤用γ计数器评估放射性示踪剂,用流式细胞术评估表达LAG-3的免疫细胞。
- 在MC38荷瘤小鼠中注射PD-1/LAG-3阻断抗体。
主要发现
- 放射性标记单域抗体在MC38、MO4和TC-1癌症模型中注射后1小时即检测到肿瘤浸润淋巴细胞上的LAG-3表达。
- 该示踪剂可视化MC38肿瘤中PD-1阻断抗体治疗小鼠TILs上LAG-3的代偿性上调。
- PD-1阻断联合LAG-3阻断时观察到肿瘤生长延迟的协同效应。
临床怎么用
- 单域抗体核素显像有望作为无创工具监测肿瘤浸润淋巴细胞LAG-3表达动态,辅助预测免疫检查点阻断治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent advances in the field of immune-oncology led to the discovery of next-generation immune checkpoints (ICPs). Lymphocyte activation gene-3 (LAG-3), being the most widely studied among them, is being explored as a target for the treatment of cancer patients. Several antagonistic anti-LAG-3 antibodies are being developed and are prime candidates for clinical application. Furthermore, validated therapies targeting cytotoxic T-lymphocyte-associated protein-4, programmed cell-death protein-1, or programmed cell-death ligand-1 showed that only subsets of patients respond. This finding highlights the need for better tools for patient selection and monitoring. The potential of molecular imaging to detect ICPs noninvasively in cancer is supported by several preclinical and clinical studies. Here, we report on a single-domain antibody to evaluate whole-body LAG-3 expression in various syngeneic mouse cancer models using nuclear imaging. Methods: SPECT/CT scans of tumor-bearing mice were performed 1 h after injection with radiolabeled single-domain antibody. Organs and tumors of mice were isolated and evaluated for the presence of the radiolabeled tracer and LAG-3-expressing immune cells using a γ-counter and flow cytometry respectively. PD-1/LAG-3-blocking antibodies were injected in MC38-bearing mice. Results: The radiolabeled single-domain antibody detected LAG-3 expression on tumor-infiltrating lymphocytes (TILs) as soon as 1 h after injection in MC38, MO4, and TC-1 cancer models. The single-domain antibody tracer visualized a compensatory upregulation of LAG-3 on TILs in MC38 tumors of mice treated with PD-1-blocking antibodies. When PD-1 blockade was combined with LAG-3 blockade, a synergistic effect on tumor growth delay was observed. Conclusion: These findings consolidate LAG-3 as a next-generation ICP and support the use of single-domain antibodies as tools to noninvasively monitor the dynamic evolution of LAG-3 expression by TILs, which could be exploited to predict therapy outcome.
引用
- Lecocq Q, Awad RM, De Vlaeminck Y, et al. Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade. J Nucl Med. 2021. PMID: 33712537. doi:10.2967/jnumed.120.258871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。